Biotech RadarJobs updated

COMPANY

iECURE

HQ: Blue Bell, PA source · iecure.com ↗

Clinical Phase 3

Keywords: gene therapy Ornithine Transcarbamylase Deficiency Ornithine Transcarbamylase Deficiency Disease Inborn Urea Cycle Disorders Ornithine Carbamoyltransferase Deficiency (Disorder) ECUR-506

Location: Blue Bell, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

  1. Trial start —: Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP) source ↗
  2. Trial start Phase 3: An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT06255782An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC DeficiencyPhase 3Active, not recruitingApr 8, 20242027-12 (estimated)
NCT06805695Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)Not listedRecruitingDec 23, 20242041-07 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback